实用医学杂志
實用醫學雜誌
실용의학잡지
THE JOURNAL OF PRACTICAL MEDICINE
2014年
9期
1450-1453
,共4页
李洪生%吴湖炳%王巧愚%韩彦江%王全师
李洪生%吳湖炳%王巧愚%韓彥江%王全師
리홍생%오호병%왕교우%한언강%왕전사
膀胱肿瘤%复发%转移%体层摄影术%发射型计算机%脱氧葡萄糖
膀胱腫瘤%複髮%轉移%體層攝影術%髮射型計算機%脫氧葡萄糖
방광종류%복발%전이%체층섭영술%발사형계산궤%탈양포도당
Urinary bladder neoplasms%Recurrence%Metastasis%Tomography%emission-computed%Deoxyglucose
目的：探讨18F-FDG PET/CT双时相显像诊断膀胱癌术后复发和转移灶的应用价值。方法：膀胱癌术后患者84例，其中临床可疑膀胱癌复发者16例，可疑转移者24例，无临床症状者44例。18F-FDG PET/CT检查时间为术后0．5～240个月，中位时间11．5个月。所有患者18F-FDG PET/CT常规全身显像后，口服40 mg呋塞米并多饮水，多次排尿，服呋塞米后约2 h憋尿充盈膀胱，再进行18F-FDG PET/CT盆腔延迟显像。膀胱癌复发病灶和转移灶的确诊，依据病理组织学检查结果或6个月以上的病例随访结果。结果：18F-FDG PET/CT显像诊断膀胱癌复发病灶的灵敏度、特异性、准确度、阳性预测值、阴性预测值分别为91．7％（22/24）、95．0％（57/60）、94．0％（79/84）、88．0％（22/25）、96．6％（57/59）；诊断膀胱癌转移病灶的灵敏度、特异性、准确度、阳性预测值、阴性预测值分别为90．0％（27/30）、96．3％（52/54）、94．0％（79/84）、93．1％（27/29）、94．5％（52/55）。结论：18F-FDG PET/CT双时相显像可以灵敏地检出膀胱癌术后的复发和转移灶，对膀胱癌术后随访及再分期具有重要的临床应用价值。
目的：探討18F-FDG PET/CT雙時相顯像診斷膀胱癌術後複髮和轉移竈的應用價值。方法：膀胱癌術後患者84例，其中臨床可疑膀胱癌複髮者16例，可疑轉移者24例，無臨床癥狀者44例。18F-FDG PET/CT檢查時間為術後0．5～240箇月，中位時間11．5箇月。所有患者18F-FDG PET/CT常規全身顯像後，口服40 mg呋塞米併多飲水，多次排尿，服呋塞米後約2 h憋尿充盈膀胱，再進行18F-FDG PET/CT盆腔延遲顯像。膀胱癌複髮病竈和轉移竈的確診，依據病理組織學檢查結果或6箇月以上的病例隨訪結果。結果：18F-FDG PET/CT顯像診斷膀胱癌複髮病竈的靈敏度、特異性、準確度、暘性預測值、陰性預測值分彆為91．7％（22/24）、95．0％（57/60）、94．0％（79/84）、88．0％（22/25）、96．6％（57/59）；診斷膀胱癌轉移病竈的靈敏度、特異性、準確度、暘性預測值、陰性預測值分彆為90．0％（27/30）、96．3％（52/54）、94．0％（79/84）、93．1％（27/29）、94．5％（52/55）。結論：18F-FDG PET/CT雙時相顯像可以靈敏地檢齣膀胱癌術後的複髮和轉移竈，對膀胱癌術後隨訪及再分期具有重要的臨床應用價值。
목적：탐토18F-FDG PET/CT쌍시상현상진단방광암술후복발화전이조적응용개치。방법：방광암술후환자84례，기중림상가의방광암복발자16례，가의전이자24례，무림상증상자44례。18F-FDG PET/CT검사시간위술후0．5～240개월，중위시간11．5개월。소유환자18F-FDG PET/CT상규전신현상후，구복40 mg부새미병다음수，다차배뇨，복부새미후약2 h별뇨충영방광，재진행18F-FDG PET/CT분강연지현상。방광암복발병조화전이조적학진，의거병리조직학검사결과혹6개월이상적병례수방결과。결과：18F-FDG PET/CT현상진단방광암복발병조적령민도、특이성、준학도、양성예측치、음성예측치분별위91．7％（22/24）、95．0％（57/60）、94．0％（79/84）、88．0％（22/25）、96．6％（57/59）；진단방광암전이병조적령민도、특이성、준학도、양성예측치、음성예측치분별위90．0％（27/30）、96．3％（52/54）、94．0％（79/84）、93．1％（27/29）、94．5％（52/55）。결론：18F-FDG PET/CT쌍시상현상가이령민지검출방광암술후적복발화전이조，대방광암술후수방급재분기구유중요적림상응용개치。
Objective To investigate the clinical value of dual phase 18F-FDG PET/CT in the diagnosis of recurrent and metastatic bladder cancer after surgery. Methods The imaging data from 84 patients underwent the dual phase 18F-FDG PET/CT after surgery with known histories of bladder cancer were analyzed. Among the 84 patients, 16 had symptoms of recurrence, 24 had symptoms of metastasis and 44 didn′t have any symptom. The median interval time between the primary tumor resection and the PET/CT scan was 11.5 months (0.5 ~ 240 months). According to the PET/CT imaging procedures, all patients underwent whole body PET/CT scan at 60 minutes after IV injection of 18F-FDG. Additional delayed pelvic PET/CT images were acquired after forced diuresis by using oral 40 mg furosemide. The 18F-FDG PET/CT findings were compared with histopathologic examination results and (or) the clinical follow-up. All patients were followed up for more than six months. Results Results of detecting recurrence and metastasis of bladder cancer showed that the sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the dual phase FDG PET/CT imaging protocol were 91.7%(22/24), 95.0%(57/60), 94.0%(79/84), 88.0%(22/25), 96.6%(57/59) and 90.0%(27/30), 96.3%(52/54), 94.0%(79/84), 93.1%(27/29), 94.5%(52/55), respectively. Conclusion Dual phase FDG PET/CT can be used to detect the recurrence and metastasis with high accuracy, contributing to the restaging and follow-up in bladder cancer after surgery.
